• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA Accepts Filing of New Estrogen-free Oral Contraceptive americanpharmaceuticalreview
    November 30, 2018
    Exeltis has received acceptance from the US Food and Drug Administration (FDA) of the filing of Slinda (4mg Drospirenone-only pill), the novel oral contraceptive developed by the company......

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service